ResearcherFirst Affiliated Hospital of Xi'an Jiaotong UniversityNo recent work listed

Yuan Hu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2230-8674; OpenAlex author ID A5054417040. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2021: 1 paper · 2022: 1 paper

Papers 2

Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma. Co-author DOI 10.4251/wjgo.v14.i7.1252 ↗
Apatinib inhibits pancreatic cancer growth, migration and invasion through the PI3K/AKT and ERK1/2/MAPK pathways. Co-author DOI 10.21037/tcr-21-207 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Enxiao Li · 2 shared papers, 2021–2022 · strength 0.26
- Paper Apatinib inhibits pancreatic cancer growth, migration and invasion through the PI3K/AKT and ERK1/2/MAPK pathways. DOI 10.21037/tcr-21-207 ↗
- Paper Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma. DOI 10.4251/wjgo.v14.i7.1252 ↗
Yangwei Fan · 1 shared paper, 2021 · strength 0.13
- Paper Apatinib inhibits pancreatic cancer growth, migration and invasion through the PI3K/AKT and ERK1/2/MAPK pathways. DOI 10.21037/tcr-21-207 ↗
Xi Wang · 1 shared paper, 2022 · strength 0.12
- Paper Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma. DOI 10.4251/wjgo.v14.i7.1252 ↗
Baojun Duan · 1 shared paper, 2022 · strength 0.12
- Paper Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma. DOI 10.4251/wjgo.v14.i7.1252 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.